Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase.

@article{Kerkela2009SunitinibinducedCI,
  title={Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase.},
  author={Risto Kerkela and Kathleen C Woulfe and J D Durand and Ronald J. Vagnozzi and David Kramer and Tammy F Chu and Cara Beahm and Ming Hui Chen and Thomas L. Force},
  journal={Clinical and translational science},
  year={2009},
  volume={2 1},
  pages={15-25}
}
Tyrosine kinase inhibitors (TKIs) are transforming the treatment of patients with malignancies. One such agent, sunitinib (Sutent, Pfizer), has demonstrated activity against a variety of solid tumors. Sunitinib is "multi-targeted," inhibiting growth factor receptors that regulate both tumor angiogenesis and tumor cell survival. However cardiac dysfunction has been associated with its use. Identification of the target of sunitinib associated cardiac dysfunction could guide future drug design to… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 80 extracted citations

Similar Papers

Loading similar papers…